pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Big Pharma · news · pharmadog
← back to Big Pharma
News · Big Pharma
309
stories
Aug 4, 26
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
Aug 4, 26
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
Aug 4, 26
Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?
endpoints
Aug 4, 26
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
Aug 4, 26
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
Aug 3, 26
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
Aug 3, 26
Amgen hit with cybersecurity breach, patient data affected
biospace
Aug 3, 26
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
Aug 3, 26
Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out
biospace
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 30, 26
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
Jul 30, 26
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
Jul 30, 26
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
Jul 30, 26
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
Jul 30, 26
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
Jul 30, 26
GSK pens $110M biological datasets pact with AI biotech Relation
fiercebiotech
Jul 30, 26
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
Jul 30, 26
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
Jul 29, 26
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
Jul 28, 26
GSK shares rise as $2.5B cost-cutting plan unveiled
biospace
Jul 28, 26
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
Jul 28, 26
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
Jul 27, 26
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
fiercebiotech
Jul 27, 26
From confidence to capital: Positioning biotech for the next growth cycle
biopharma dive
Jul 27, 26
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
biospace
Jul 27, 26
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
Jul 24, 26
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
← prev
page 9 of 11
next →